Viiv Healthcare

This study tests the safety and how the body handles the drug cabotegravir in newborns (up to 10 days old) who were exposed to HIV-1. About 44 healthy babies born at full term and weighing at least 2 kg will receive the drug either by mouth or injection. The goal is to find safe …

This early-stage study is testing a new long-acting injectable drug called VH4524184 in 268 healthy adults. The goal is to see if it is safe and how the body processes it, as a potential new treatment for HIV. Participants receive either the drug or a placebo, and researchers mon…

This study tests if a long-acting injectable HIV medication (CAB LA + RPV LA) can suppress the virus better than daily pills in people who still have detectable HIV despite oral treatment. About 332 participants will receive either the injections or continue standard oral therapy…

This study tests a new oral drug, VH4524184, taken with two standard HIV medicines (emtricitabine and tenofovir alafenamide) in 150 adults with HIV-1 who have never received treatment. The goal is to see if the new combination can suppress the virus as well as a current standard …

This study is checking the long-term safety and effectiveness of a long-acting injectable drug called cabotegravir (CAB LA) for preventing HIV. It includes about 3,500 people who already received CAB LA in earlier HIV prevention studies. Participants will continue getting the sho…

This early-stage study is testing a new long-acting injectable drug, VH4011499, to see if it is safe and tolerable for preventing HIV. About 168 healthy adults without HIV will receive one or more doses as a shot under the skin or into a muscle. Researchers will monitor side effe…

This early-stage study is testing a long-acting HIV drug called cabotegravir in 214 healthy adults. The goal is to see how the drug moves through the body and if it is safe when given as a shot. Participants do not have HIV and will not receive any direct treatment benefit, but t…